Somatotropin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Somatotropin: From Growth Hormone Therapy to Middle Ear Neuroendocrine Tumor
One-Sentence Summary
Somatotropin (recombinant human growth hormone, rhGH) is established therapy for growth hormone deficiency and related growth disorders; the evidence pack does not specify a formal original indication for this candidate. The TxGNN model’s top-ranked prediction points to Middle Ear Neuroendocrine Tumor, but this is supported by 0 clinical trials and only 2 loosely related publications, and the underlying biology (GH/IGF‑1-driven cell proliferation) argues against rather than for a therapeutic role.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (data gap); Somatotropin is clinically established for growth hormone deficiency |
| Predicted New Indication | Middle Ear Neuroendocrine Tumor |
| TxGNN Prediction Score | 96.82% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Somatotropin activates the growth hormone receptor → JAK2/STAT5 pathway, stimulating hepatic IGF‑1 production and promoting cell growth and proliferation — a mechanism generally used to correct growth deficiency, not to treat tumours.
The two supporting publications do not establish a therapeutic rationale. One examines stress hormones (including GH) in Ménière’s disease and acoustic neuroma patients as a correlational, observational finding; the other studies histopathological growth factors in vestibular schwannoma without any reference to GH administration or treatment. Neither paper tests, nor supports, giving Somatotropin to treat a neuroendocrine tumour.
Mechanistically, the proliferative action of the GH/IGF‑1 axis is more plausibly a safety liability than a benefit in a tumour-bearing patient. This prediction should be read as a model-generated hypothesis with no experimental or clinical grounding, and the directionality of the proposed mechanism (growth promotion) is inconsistent with treating a neoplasm.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15925138 | 2005 | Cohort | Brain Research Bulletin | Correlational study of stress hormones (including GH) in Ménière’s disease and acoustic neuroma patients vs. facial spasm controls; found correlation between cortisol and ACTH, not a treatment finding. |
| 11200590 | 2000 | Cohort | Acta Oto-Laryngologica | Immunohistochemical study of growth factors and vascularity in 69 vestibular schwannomas; does not involve GH administration or therapeutic intervention. |
UK Market Information
Somatotropin currently holds no MHRA marketing authorisation in the United Kingdom (0 licences on record; market status: not marketed). No UK product information is therefore available for this candidate.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Product label warnings and contraindications for this candidate are currently a Blocking data gap (DG001), which prevents entry into the formal safety pre-assessment stage (S1). Mechanism of action detail is also flagged as a High-severity gap (DG002).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 — no clinical trials and only two indirectly related, non-interventional publications exist for this indication. The proposed GH/IGF‑1 proliferative mechanism is directionally inconsistent with treating a neoplasm, and a Blocking safety data gap (missing warnings/contraindications) prevents any formal safety review.
To proceed, the following is needed:
- Product label (SmPC) warnings and contraindications (Blocking gap, DG001)
- Detailed mechanism of action data (DG002)
- Dedicated pharmacological or preclinical evidence directly examining GH signalling in middle ear neuroendocrine tumours (current literature is only tangentially related)
- Confirmation of UK regulatory pathway, since the product currently has no UK marketing authorisation
Note: This evidence pack contains 10 ranked candidates for Somatotropin, and rank 1 (reported above) is not the strongest. Rank 5, mixed gonadal dysgenesis, has materially stronger support — evidence level L1, including a completed Phase 3 RCT (NCT00191113, Humatrope in Turner syndrome, n=154) — with a recommendation of “Proceed with Guardrails.” A separate report on that candidate may be of greater practical value.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.